Tag: #SGLT2Inhibitors
-
Empagliflozin and Water Retention A Breakthrough in Type 2 Diabetes Management
Introduction: Managing type 2 diabetes mellitus (T2DM) involves addressing multiple metabolic complications, including kidney function and water balance. A recent study published in the Journal of Clinical Nephrology explores how empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, influences water retention through prostaglandin E2 (PGE2) responses in the collecting duct (CD). This research sheds light…
-
SGLT2 Inhibitors and Nephroprotection Advancing Treatment for Diabetic Kidney Disease
Introduction: Diabetic kidney disease (DKD) remains a leading cause of end-stage renal failure worldwide, contributing significantly to morbidity and mortality in individuals with Type 2 Diabetes Mellitus (T2D). Recent advancements highlight the potential of sodium-glucose cotransporter-2 (SGLT2) inhibitors as a groundbreaking therapeutic approach. These drugs not only regulate blood glucose levels but also provide nephroprotective…
Heighten Science Publications Inc. 